Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01XUE
|
|||
| Former ID |
DNCL003059
|
|||
| Drug Name |
Tedatioxetine
|
|||
| Synonyms |
TEDATIOXETINE; 508233-95-2; UNII-5H681S8O3S; Lu AA24530; 5H681S8O3S; Tedatioxetine [USAN:INN]; Tedatioxetine (USAN); 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine; SCHEMBL547653; Lu-AA24530; CHEMBL2104986; Lu-AA-24530; ZINC34003654; DB12641; SB16713; D10170; Piperidine, 4-(2-((4-methylphenyl)thio)phenyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Generalized anxiety disorder [ICD-11: 6B00; ICD-10: F41.1] | Phase 1 | [1] | |
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Phase 1 | [1] | ||
| Company |
Lundbeck; Takeda Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21NS
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)SC2=CC=CC=C2C3CCNCC3
|
|||
| InChI |
1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3
|
|||
| InChIKey |
CVASBKDYSQKLSO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 508233-95-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2C receptor (HTR2C) | Target Info | Modulator | [2] |
| 5-HT 3 receptor (5HT3R) | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023694) | |||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.